You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • SAT0543 Reduced/Withdrawn Dose of Etanercept-Methotrexate Therapy of Early Rheumatoid Arthritis has a Favorable Impact on Patient-Reported Outcomes Compared with MTX Alone or Placebo: the Prize Study

Citation Tools

Article menu
Download PDFPDF
Scientific Abstracts
Epidemiology, health services and outcome research
SAT0543 Reduced/Withdrawn Dose of Etanercept-Methotrexate Therapy of Early Rheumatoid Arthritis has a Favorable Impact on Patient-Reported Outcomes Compared with MTX Alone or Placebo: the Prize Study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Emery P, Wiland P, Dudler J, et al
SAT0543 Reduced/Withdrawn Dose of Etanercept-Methotrexate Therapy of Early Rheumatoid Arthritis has a Favorable Impact on Patient-Reported Outcomes Compared with MTX Alone or Placebo: the Prize Study
Annals of the Rheumatic Diseases 2013;72:A765-A766.